AMSilk Announces the Addition of Jeff Davis to its Advisory Board
News Apr 10, 2012
AMSilk has announced the appointment of Jeff Davis, a senior business executive, to AMSilk’s advisory board.
Jeff Davis brings with him more than 23 years of executive experience in sales, marketing and general management in global pharmaceuticals, consumer package goods and beauty businesses from Procter & Gamble, a world leader in consumer care products.
Jeff served in several key roles at P&G including: director of global new business development at P&G Pharmaceuticals; he spearheaded the opening of new markets in Eastern Europe in the early nineties and served as global Vice President & General Manager of Wella, Germany, after its acquisition through P&G.
Jeff has worked in 6 different product groups and 5 different countries.
More recently, as the CEO of Orabrush Inc., an innovative oral care product company targeting the young consumer, Jeff has developed marketing strategies for consumer products using social media with unprecedented success.
He, lectures as an adjunct Professor at the David Eccles School of Business at the University of Utah, and advises Ernst & Young’s business consulting practice for their elite worldwide clients.
“Jeff’s contributions to our product strategy are already significant and this couldn’t have come at a better time,” says Axel Leimer, CEO of AMSilk.
Leimer continued, “AMSilk’s ambitious goals of bringing Spidersilk and related novel high performance materials to market will benefit greatly from his experience.”
“I am excited to work with AMSilk. Having followed AMSilk for some time, I have seen the focus shift from technology to product development,” says Jeff.
Jeff continued, “Spidersilk is a true cleantech material for safer products with a new range of properties. It shows what is possible if we learn from nature.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE